Your session is about to expire
What is Daklinza
DaclatasvirThe Generic name of this drug
Treatment SummaryDaclatasvir is an oral medication used to treat chronic Hepatitis C Virus (HCV) infection. It is a direct-acting antiviral agent that prevents the virus from replicating and is usually used in combination with other drugs. It is FDA-approved to treat HCV genotypes 1 and 3 infections in both adults and children, with or without cirrhosis. Common side effects of treatment include fatigue, headaches, and nausea. Studies have shown that daclatasvir combined with other medications can achieve a sustained viral response (SVR12) in over 90% of patients with HCV genotype 1 or
Daklinzais the brand name
Daklinza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Daklinza
Daclatasvir
2015
3
Approved as Treatment by the FDA
Daclatasvir, otherwise called Daklinza, is approved by the FDA for 2 uses like Hepatitis C and Hepatitis C .Hepatitis C
Used to treat Chronic Hepatitis C - Genotype 3 in combination with Ribavirin
Hepatitis C
Used to treat Chronic Hepatitis C Genotype 1 in combination with Ribavirin
Effectiveness
How Daklinza Affects PatientsDaclatasvir is a drug that stops the hepatitis C virus from replicating in the body. It works by targeting a specific protein (NS5A) that is needed to make copies of the virus and prevents it from working properly. It is safe to take, even at doses three times higher than the recommended amount, and does not have any effect on the electrical activity in the heart.
How Daklinza works in the bodyNS5A is a protein found in the cells of patients with Hepatitis C. It helps the virus to reproduce by binding to its genetic material and helping to create new copies of the virus. Daclatasvir stops this process by disrupting the proteins that help with the reproduction of the virus. It also prevents it from forming new copies of itself and spreading to other cells.
When to interrupt dosage
The suggested dosage of Daklinza is contingent upon the diagnosed condition, for instance Hepatitis C, Hepatitis C and HIV Positive. The amount of dosage can be found in the table below, relative to the mode of administration (e.g. Tablet or Oral).Condition
Dosage
Administration
Chronic hepatitis C genotype 2
, 60.0 mg, 30.0 mg, 90.0 mg
, Oral, Tablet, Tablet - Oral
HIV Positive
, 60.0 mg, 30.0 mg, 90.0 mg
, Oral, Tablet, Tablet - Oral
Hepatitis C
, 60.0 mg, 30.0 mg, 90.0 mg
, Oral, Tablet, Tablet - Oral
Hepatitis C
, 60.0 mg, 30.0 mg, 90.0 mg
, Oral, Tablet, Tablet - Oral
Chronic Hepatitis C
, 60.0 mg, 30.0 mg, 90.0 mg
, Oral, Tablet, Tablet - Oral
Warnings
Daklinza ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
suspected pregnancy
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Daclatasvir may interact with Pulse Frequency
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Common Daklinza Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Daclatasvir.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Daclatasvir.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Daclatasvir.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Daclatasvir.
Binimetinib
Major
The serum concentration of Binimetinib can be increased when it is combined with Daclatasvir.
Daklinza Toxicity & Overdose RiskCommon side effects from taking daclatasvir and sofosbuvir include headache, tiredness, nausea, and diarrhea. If ribavirin is added to the treatment, there may be additional side effects such as rash, difficulty sleeping, anemia, dizziness, and drowsiness. Taking all three drugs together (daclatasvir, sofosbuvir, and amiodarone) can cause a serious decrease in heart rate and is not advised unless there is no other choice.
Daklinza Novel Uses: Which Conditions Have a Clinical Trial Featuring Daklinza?
An active clinical trial is currently evaluating the potential of Daklinza to provide relief from Hepatitis C, Chronic hepatitis C genotype 2 and Hepatitis C.Condition
Clinical Trials
Trial Phases
Hepatitis C
0 Actively Recruiting
HIV Positive
0 Actively Recruiting
Hepatitis C
0 Actively Recruiting
Chronic hepatitis C genotype 2
0 Actively Recruiting
Chronic Hepatitis C
1 Actively Recruiting
Phase 2
Daklinza Reviews: What are patients saying about Daklinza?
5Patient Review
5/31/2016 I've been taking daklinza and solvadi for hep c geno 3, and I haven't had any side effects to speak of. I make sure to drink plenty of water everyday because dehydration seems to be the only problem. I'll take my last pill today, and so far there's no virus detected. Stay positive!!!
4.7Patient Review
12/31/2015 I'm nearing the end of a 12-week treatment, and things are looking great so far. My last two lab tests showed no viral load and normal liver enzymes. I take Daklinza with Sovaldi. The worst side effect for me has been stomach upset, but my doctor says the emotional part is due to anxiety and I am taking Valium to help with that. I really believe and pray this is my CURE. It took 5 long years before a treatment came along that my hepatologist felt I could handle.
4Patient Review
10/25/2015 I've been taking daklinza and sovaldi for a little over a month now, and I feel great! There's the occasional nausea, but mostly just joint pain. My doctor is excited about my progress so far. I'm waiting on my first round of bloodwork results, but wanted to share my early feelings about this medication.
Patient Q&A Section about daklinza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How is daclatasvir administered?
"DAKLINZA should be taken at a dose of 60 mg, once per day, orally. It can be taken with or without food."
Answered by AI
How much does Daklinza cost?
"When Daklinza (daclatasvir) was available, the price for a 12-week course was around $63,000, but patients paid a range from $72,000 to $75,000. Bristol Myers Squibb discontinued Daklinza and the generic daclatasvir in 2019 due to business reasons."
Answered by AI
Is Daklinza discontinued?
": FDA announced Bristol Myers Squibb is discontinuing Daklinza 30mg and 60mg tablets. This follows the discontinuation of Daklinza 90mg tablets announced earlier, with distribution set to end in Dec 2018."
Answered by AI
What is Daklinza used for?
"Daklinza is an antiviral medicine that is used in combination with other medications to treat chronic hepatitis c in adults. Daklinza is effective against specific genotypes of hepatitis C, and is only indicated for certain people."
Answered by AI